Supplemental material
Cancer Biology & Therapy
Volume 25, 2024 - Issue 1
Research Paper
CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
, , , , & 
André Liebera Department of Medicine, University of Washington, Seattle, WA, USA;b Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA;c R&D, Compliment Corp, Seattle, WA, USACorrespondence[email protected]
https://orcid.org/0000-0001-6742-6266View further author information
https://orcid.org/0000-0001-6742-6266View further author information